Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:59 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma
NCT05170789 · Tulane University School of Medicine · PHASE2 · withdrawn · last registry update 2022-05-04 · Multiple myeloma · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study collaborator -Karyopharm- is not doing Myeloma studies funding, so they let the study investigators know they are not funding the study anymore.” | Open Targets' class: business administrative | Registry record, Tulane University School of Medicine |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLAMF7 in multiple myeloma within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-03-29Also stopped (terminated): H. Lee Moffitt Cancer Center and Research Institute, Elotuzumab + Lenalidomide (NCT03411031)
- 2023-03-27Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Elotuzumab (NCT02726581)
- 2023-02-15Phase 3 first posted: Regeneron Pharmaceuticals, Linvoseltamab + Elotuzumab (NCT05730036)
- 2023-01-09Phase 3 first posted: Universitätsklinikum Hamburg-Eppendorf, Allogeneic Stem Cells + carfilzomib/lenalidomide/dexamethasone (KRD) (NCT05675319)
- 2022-10-17Results posted on the registry: SCRI Development Innovations, LLC, elotuzumab + Lenalidomide (NCT02843074)
- 2022-07-26Results posted on the registry: Wake Forest University Health Sciences, Elotuzumab (NCT03361306)
- 2022-04-14Results posted on the registry: H. Lee Moffitt Cancer Center and Research Institute, Elotuzumab + Lenalidomide (NCT03411031)
- 2022-03-31Also stopped (terminated): Oncotherapeutics, Elotuzumab + Pomalidomide (NCT03104270)
- 2021-10-27Results posted on the registry: SWOG Cancer Research Network, Bortezomib + Dexamethasone (NCT01668719)
- 2021-08-31Phase 3 first posted: European Myeloma Network B.V., Selinexor + Elotuzumab (NCT05028348)
- 2021-08-23Also stopped (withdrawn): Natalie Callendar, Elotuzumab + Pomalidomide (NCT04584307)
- 2021-07-01Results posted on the registry: Bristol-Myers Squibb, Lenalidomide + Dexamethasone (NCT01891643)
- 2021-07-01Also stopped (terminated): Bristol-Myers Squibb, Lenalidomide + Dexamethasone (NCT01891643)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision